Lilly gets limited European backing for Alzheimer’s drug
Lilly previously secured approval for Kisunla in the U.S., Japan and the U.K.
Eli Lilly and Co.
Articles
IBJ names 20 in their Twenties honorees for 2025
The up-and-coming leaders represent business, the arts and culture, philanthropy, government and community service.
Drugmaker telehealth deals risk unnecessary prescribing, Senate probe finds
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.
Prices for obesity drugs fall, but affordability still out of reach for many
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.
Lilly drug saves muscle when added to Wegovy weight-loss shot
The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.
Lilly hosts Reddit ‘Ask Me Anything’ Q&A on blockbuster weight-loss drug Zepbound
Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk’s Wegovy.
Lilly acquires cardiovascular genetic medicine company for up to $1.3B
Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.
Lilly says weight loss pill has vast opportunity
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Lilly, Purdue Strategic Ventures invest in AI-assisted remote lab platform built for speedier research and development
Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.
Reports: Lilly eyes Houston for new $5.9B manufacturing facility
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.
Lilly seeks to expand pain pipeline with $1B acquisition
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and sensory hyperexcitability disorders.
Novo to sell Wegovy at $199 a month as copycat availability ends
On Thursday, pharmacies were supposed to stop making the copies of the medications that had become popular during shortages of the brand-name drugs.
Tobias, Lechleiter families donate $20M for clinical innovation, matched by IU Health
The Tobias-Lechleiter Institute will focus on getting more Hoosiers enrolled in clinical trials and advancing medical research at IU Health and the IU School of Medicine.
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.
‘Innovation at every stage’: Lilly to invest up to $250M in broadened alliance with Purdue University
The extended partnership holds the potential to be the largest industry-academic agreement of its kind in the United States, Purdue President Mung Chiang said.
Lilly shuffles roles amid growth in U.S. investment, diabetes and obesity treatments
The company has announced more than $50 billion in new U.S. manufacturing investments since 2020.
Lilly chief scientist talks drugmaker’s new $4.5B campus, recruiting and innovation
Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the Indianapolis-based drugmaker broke ground on this week.
Lilly breaks ground on $4.5B foundry campus in Lebanon’s LEAP District
Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of discovering new medicines and getting them to patients.
UPDATE: Lilly shares tumble after missing analyst earnings expectations
The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.